drug_type
RELEVANT_DRUG
intervention_type
Biological (bispecific T-cell engager antibody)
drug_description
An intravenous bispecific T-cell engager (BiTE) antibody (AMG 757; IMDELLTRA) that binds DLL3 on SCLC tumor cells and CD3 on T cells, creating an immune synapse to activate TCR/CD3 signaling and redirect T-cell cytotoxicity against DLL3-expressing cells.
nci_thesaurus_concept_id
C175858
nci_thesaurus_preferred_term
Tarlatamab
nci_thesaurus_definition
A bispecific T-cell engager (BiTE) antibody composed of two single-chain variable fragments (scFv), one directed against the tumor-associated antigen (TAA) delta-like protein 3 (DLL3) fused to one that is directed against the CD3 antigen found on T-lymphocytes, with potential immunostimulating and antineoplastic activities. Upon administration, tarlatamab binds to both the CD3 antigen on cytotoxic T-lymphocytes (CTLs) and the DLL3 antigen found on DLL3-expressing tumor cells. This activates and redirects CTLs to DLL3-expressing tumor cells, which results in the CTL-mediated cell death of DLL3-expressing tumor cells. DLL3, a Notch pathway protein, is overexpressed on a variety of cancer cell types. It plays a key role in embryonic development and in tumor initiation and proliferation.
drug_mesh_term
AMG 757
drug_category
BISPECIFIC T ENGAGER
drug_class
Engager
drug_delivery_route
Intravenous
drug_mechanism_of_action
Bispecific T-cell engager antibody that binds DLL3 on tumor cells and CD3 on T cells, creating an immune synapse that activates TCR/CD3 signaling and redirects T-cell cytotoxicity to kill DLL3-expressing cells (e.g., SCLC).
drug_name
Tarlatamab
nct_id_drug_ref
NCT06502977